Contact
Contact

2020

Payer Intelligence: How Can It Be Combined With Technology to Enhance Patient Access?

The New Sales Model: Virtual Engagement in the Time of COVID-19 August 10th, 2020 Scott Dulitz, Chief Strategy Officer at TrialCard, discusses how combining payer intelligence with market-leading technology can enhance patient access. TrialCard recently acquired Policy Reporter, a healthcare software solutions company that provides payer intelligence to the biopharmaceutical, medical device, and diagnostics industries. To learn more, schedule a demo of Policy Reporter or contact Scott (scott.dulitz@trialcard.com). The healthcare industry is entering an unprecedented era of medical innovation with several recent approvals for curative cell and gene therapies, novel digital therapeutics, [...]

Payer Intelligence: How Can It Be Combined With Technology to Enhance Patient Access?2021-01-16T14:19:20-05:00

Clinical Supply Availability & Speed to Study Start-Up

The New Sales Model: Virtual Engagement in the Time of COVID-19 August 10th, 2020 The Situation If you're part of a clinical study team racing a new product to commercialization, you likely live by these two simple rules: time is money, and the first one to market wins. But just because it's simple doesn't mean it's easy. That ticking clock is background noise to the responsibilities of regulations, study protocols, supply chains, and patient recruitment — all the details that must be worked out before a study can even begin. [...]

Clinical Supply Availability & Speed to Study Start-Up2021-01-16T14:19:52-05:00

COVID-19: A Message from President & CEO, Mark Bouck

The New Sales Model: Virtual Engagement in the Time of COVID-19 August 10th, 2020 Over the past few weeks, all of us have been impacted by the COVID-19 pandemic. As we continue to adjust to these changing times, I wanted to update you on steps that TrialCard has taken to expand our business continuity plan. Our immediate goals are to (1) ensure the safety and well-being of our employees, (2) implement preventative measures to reduce the risk of exposure, and (3) continue to support our pharmaceutical manufacturers and their patients. We [...]

COVID-19: A Message from President & CEO, Mark Bouck2021-01-16T14:20:05-05:00

Rare is mighty. Rare is exceptional.

The New Sales Model: Virtual Engagement in the Time of COVID-19 August 10th, 2020 Rare disease is defined as affecting fewer than 200,000 people. So, there is something about the term “rare disease”….when you hear that phrase….you think of that singular patient, that very particular and unique person. In fact, every day that I begin my work in the world of rare disease, I pause and reflect on that one patient that I may be fortunate enough to help. And sometimes, our perspective can shift in wonderful ways... In January, [...]

Rare is mighty. Rare is exceptional.2021-01-16T14:20:13-05:00
Go to Top